WO2003068937A3 - Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells - Google Patents

Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells Download PDF

Info

Publication number
WO2003068937A3
WO2003068937A3 PCT/US2003/004539 US0304539W WO03068937A3 WO 2003068937 A3 WO2003068937 A3 WO 2003068937A3 US 0304539 W US0304539 W US 0304539W WO 03068937 A3 WO03068937 A3 WO 03068937A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
embryonic
cells
stem
post
Prior art date
Application number
PCT/US2003/004539
Other languages
French (fr)
Other versions
WO2003068937A2 (en
Inventor
Robert J Hariri
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/076,180 external-priority patent/US20030032179A1/en
Priority to CA002476553A priority Critical patent/CA2476553A1/en
Priority to EP03739817A priority patent/EP1482787A4/en
Priority to AU2003216286A priority patent/AU2003216286B2/en
Priority to JP2003568052A priority patent/JP2005517402A/en
Priority to KR1020047012604A priority patent/KR101176146B1/en
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Priority to MXPA04007732A priority patent/MXPA04007732A/en
Priority to NZ534643A priority patent/NZ534643A/en
Publication of WO2003068937A2 publication Critical patent/WO2003068937A2/en
Publication of WO2003068937A3 publication Critical patent/WO2003068937A3/en
Priority to IL163439A priority patent/IL163439A/en
Priority to IL207763A priority patent/IL207763A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0462—Placental blood, umbilical cord blood

Abstract

The present invention provides compositions and methods of using embryonic-like stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The embryonic-like stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the embryonic-like stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The embryonic-like stem cells and the mixed populations of embryonic-like stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.
PCT/US2003/004539 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells WO2003068937A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NZ534643A NZ534643A (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
EP03739817A EP1482787A4 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
AU2003216286A AU2003216286B2 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
JP2003568052A JP2005517402A (en) 2002-02-13 2003-02-13 Embryo-like stem cells derived from the post-partum mammalian placenta, uses of the cells and therapeutic methods using the cells
KR1020047012604A KR101176146B1 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
CA002476553A CA2476553A1 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
MXPA04007732A MXPA04007732A (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells.
IL163439A IL163439A (en) 2002-02-13 2004-08-10 Compositions comprising embryonic-like stem cells derived from post-partum mammalian placenta and human stem or progenitor cells and kits comprising such compositions
IL207763A IL207763A (en) 2002-02-13 2010-08-24 Use of placental stem cells and umbilical cord blood cells for preparing a medicament for treating diseases and injuries

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/076,180 2002-02-13
US10/076,180 US20030032179A1 (en) 2000-12-06 2002-02-13 Post-partum mammalian placenta, its use and placental stem cells therefrom
US43729202P 2002-12-31 2002-12-31
US60/437,292 2002-12-31

Publications (2)

Publication Number Publication Date
WO2003068937A2 WO2003068937A2 (en) 2003-08-21
WO2003068937A3 true WO2003068937A3 (en) 2004-04-22

Family

ID=42186393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004539 WO2003068937A2 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells

Country Status (10)

Country Link
EP (1) EP1482787A4 (en)
JP (2) JP2005517402A (en)
KR (2) KR101176146B1 (en)
AU (2) AU2003216286B2 (en)
CA (1) CA2476553A1 (en)
IL (2) IL163439A (en)
MX (1) MXPA04007732A (en)
NZ (1) NZ534643A (en)
WO (1) WO2003068937A2 (en)
ZA (1) ZA200406356B (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889411B2 (en) 2002-04-12 2014-11-18 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US8895256B2 (en) 2005-10-13 2014-11-25 Anthrogenesis Corporation Immunomodulation using placental stem cells
US8916146B2 (en) 2007-02-12 2014-12-23 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US8926964B2 (en) 2010-07-13 2015-01-06 Anthrogenesis Corporation Methods of generating natural killer cells
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9121007B2 (en) 2010-01-26 2015-09-01 Anthrogenesis Corporatin Treatment of bone-related cancers using placental stem cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9149569B2 (en) 2000-12-06 2015-10-06 Anthrogenesis Corporation Treatment of diseases or disorders using placental stem cells
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
US9216200B2 (en) 2007-09-28 2015-12-22 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US9234172B2 (en) 2003-06-27 2016-01-12 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US9254302B2 (en) 2010-04-07 2016-02-09 Anthrogenesis Corporation Angiogenesis using placental stem cells
US9339520B2 (en) 2006-10-23 2016-05-17 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US9498501B2 (en) 2003-06-27 2016-11-22 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9598669B2 (en) 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050105467A (en) * 2003-02-13 2005-11-04 안트로제네시스 코포레이션 Use of umbilical cord blood to treat individuals having a disease, disorder or condition
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US8088585B2 (en) 2003-10-31 2012-01-03 Children's Medical Center Corporation Methods for purifying hematopoietic stem cells
US7816137B2 (en) 2004-01-30 2010-10-19 Lifecord Inc. Method for isolating and culturing multipotent progenitor cells from umbilical cord blood
CN101080486B (en) * 2004-04-23 2012-05-16 佰欧益股份有限公司 Multi-lineage progenitor cells
US8309070B2 (en) 2004-05-17 2012-11-13 Regents Of The University Of Minnesota Use of umbilical cord blood stem cells to treat ischemic event
WO2006015214A2 (en) * 2004-07-29 2006-02-09 Steenblock Research Institute, Inc. Umbilical cord stem cell composition & method of treating neurological diseases
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
MX2007001937A (en) 2004-08-16 2007-08-07 Cellres Corp Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord.
EP1831355A2 (en) * 2004-12-23 2007-09-12 Ethicon, Inc. Soft tissue repair and regeneration using postpartum-derived cells and cell products
AU2005322068B2 (en) 2004-12-23 2011-09-01 Ethicon Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
EP1838842A2 (en) * 2004-12-23 2007-10-03 Ethicon, Incorporated Treatment of osteochondral diseases using postpartum-derived cells and products thereof
JP2007528229A (en) * 2005-08-26 2007-10-11 ソウル ナショナル ユニバーシティ インダストリー ファウンデーション Pluripotent stem cell isolated from umbilical cord blood and cell therapeutic agent for treating ischemic necrosis disease containing the same
EP1941890A4 (en) * 2005-09-16 2009-08-05 Kenji Yoshida Hematopoietic stem cell proliferator
JP2007106760A (en) * 2005-09-16 2007-04-26 Kenji Yoshida Hematopoietic stem cell proliferator
DK1941031T3 (en) 2005-10-05 2014-03-31 Univ Illinois Isolated embryonic-like stem cells derived from human umbilical cord blood
US9388382B2 (en) 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
NZ567334A (en) 2005-10-13 2012-08-31 Anthrogenesis Corp Production of oligodendrocytes from placenta-derived stem cells
US8048999B2 (en) * 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
WO2007070870A1 (en) 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
WO2007076522A2 (en) * 2005-12-28 2007-07-05 Ethicon, Incorporated Treatment of peripheral vascular disease using postpartum-derived cells
AU2014201181B2 (en) * 2005-12-29 2017-07-20 Celularity Inc. Placental stem cell populations
ES2549111T3 (en) 2005-12-29 2015-10-23 Anthrogenesis Corporation Placental stem cell populations
EP1976978A2 (en) * 2005-12-29 2008-10-08 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
US9944900B2 (en) 2006-01-18 2018-04-17 Hemacell Perfusion Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells
US7727763B2 (en) * 2006-04-17 2010-06-01 Bioe, Llc Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
EP2023717B1 (en) 2006-05-11 2016-04-13 Anthrogenesis Corporation Methods for collecting placenta cord blood stem cells
CA2666789C (en) 2006-10-18 2016-11-22 Yong Zhao Embryonic-like stem cells derived from adult human peripheral blood and methods of use
KR100812544B1 (en) * 2006-10-19 2008-03-13 재단법인서울대학교산학협력재단 Multipotent Stem Cells Isolated from Umbilical Cord Blood and the Cellular Therapeutic Agent Comprising the Same for Treating Ischemic Disease
KR20090109127A (en) 2007-02-12 2009-10-19 안트로제네시스 코포레이션 Hepatocytes and chondrocytes from adherent placental stem cells? and cd34?, cd45? placental stem cell-enriched cell populations
AU2014203165B2 (en) * 2007-02-12 2016-08-11 Celularity Inc. Treatment of inflammatory diseases using placental stem cells
WO2008109816A1 (en) 2007-03-08 2008-09-12 Hemacell Perfusion, Inc. Method for isolation of afterbirth derived cells
PL2200622T5 (en) 2007-09-19 2016-08-31 Pluristem Ltd Adherent cells from adipose or placenta tissues and use thereof in therapy
AU2013267050B2 (en) * 2007-09-19 2016-01-07 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
CN101978045A (en) * 2007-09-26 2011-02-16 细胞基因细胞疗法公司 Angiogenic cells from human placental perfusate
KR20210056449A (en) * 2007-11-07 2021-05-18 안트로제네시스 코포레이션 Use of umbilical cord blood in the treatment of premature birth complications
EP3539380A3 (en) 2008-08-20 2019-12-18 Celularity, Inc. Improved cell composition and methods of making the same
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
CA2747794C (en) 2008-12-19 2018-10-30 Advanced Technologies And Regenerative Medicine, Llc Treatment of lung and pulmonary diseases and disorders
BRPI1013409A2 (en) 2009-03-26 2018-01-16 Advanced Tech And Regenerative Medicine Llc human umbilical cord tissue cells as therapy for alzheimer's disease
CA2767014C (en) 2009-07-02 2022-01-25 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
CA2787894A1 (en) 2010-01-26 2011-08-04 Stem Cells Spin S.A. Cell homogenate from stem cells derived from growing deer antlers, a method of obtaining it and its use
TWI602570B (en) 2011-06-01 2017-10-21 安瑟吉納西斯公司 Treatment of pain using placental stem cells
MX362198B (en) 2011-12-23 2019-01-08 Depuy Synthes Products Llc Detection of human umbilical cord tissue-derived cells.
EP3622960A1 (en) 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta
PT2968420T (en) * 2013-03-14 2019-01-11 Celularity Inc Use of placental stem cells in treatment of acute kidney injury
EP2970913B1 (en) 2013-03-15 2018-08-22 LongBoat Explorers AB Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells
KR20160075676A (en) 2013-10-24 2016-06-29 오스페달레 산 라파엘 에스.알.엘. Method
FR3035407B1 (en) 2015-04-23 2022-06-17 Francais Du Sang Ets METHOD FOR PRESERVING CELLS, TISSUES OR ORGANS IN HYPOTHERMIA
FR3040860B1 (en) * 2015-09-10 2020-05-15 Universite de Bordeaux INJECTABLE STORAGE MEDIUM FOR STORAGE OF PLACENTAL BLOOD, BONE MARROW AND PERIPHERAL BLOOD CELLS
WO2018073615A1 (en) 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
US20220372444A1 (en) 2019-10-18 2022-11-24 Amniotics Ab Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861315A (en) * 1994-11-16 1999-01-19 Amgen Inc. Use of stem cell factor and soluble interleukin-6 receptor for the ex vivo expansion of hematopoietic multipotential cells
US6146888A (en) * 1993-04-21 2000-11-14 The University Of Edinburgh Method of enriching for mammalian stem cells
US6179819B1 (en) * 1996-08-30 2001-01-30 John N. Haswell Umbilical cord blood collection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
AU7611500A (en) * 1999-09-24 2001-04-24 Abt Holding Company Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
IL156303A0 (en) * 2000-12-06 2004-01-04 Robert J Hariri Method of collecting placental stem cells
EP1362095B1 (en) * 2001-02-14 2015-05-27 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146888A (en) * 1993-04-21 2000-11-14 The University Of Edinburgh Method of enriching for mammalian stem cells
US5861315A (en) * 1994-11-16 1999-01-19 Amgen Inc. Use of stem cell factor and soluble interleukin-6 receptor for the ex vivo expansion of hematopoietic multipotential cells
US6179819B1 (en) * 1996-08-30 2001-01-30 John N. Haswell Umbilical cord blood collection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG ET AL.: "Enhanced recovery of hematopoietic progenitor and stem cells from cultivated, postpartum human placenta", BLOOD, vol. 98, 16 November 2001 (2001-11-16), pages 183A, XP001085063 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149569B2 (en) 2000-12-06 2015-10-06 Anthrogenesis Corporation Treatment of diseases or disorders using placental stem cells
US8889411B2 (en) 2002-04-12 2014-11-18 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9498501B2 (en) 2003-06-27 2016-11-22 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9234172B2 (en) 2003-06-27 2016-01-12 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US9539288B2 (en) 2005-10-13 2017-01-10 Anthrogenesis Corporation Immunomodulation using placental stem cells
US8895256B2 (en) 2005-10-13 2014-11-25 Anthrogenesis Corporation Immunomodulation using placental stem cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9585918B2 (en) 2005-12-28 2017-03-07 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9598669B2 (en) 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition
US9339520B2 (en) 2006-10-23 2016-05-17 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US8916146B2 (en) 2007-02-12 2014-12-23 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
US9216200B2 (en) 2007-09-28 2015-12-22 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US9121007B2 (en) 2010-01-26 2015-09-01 Anthrogenesis Corporatin Treatment of bone-related cancers using placental stem cells
US9254302B2 (en) 2010-04-07 2016-02-09 Anthrogenesis Corporation Angiogenesis using placental stem cells
US8926964B2 (en) 2010-07-13 2015-01-06 Anthrogenesis Corporation Methods of generating natural killer cells
US9464274B2 (en) 2010-07-13 2016-10-11 Anthrogenesis Corporation Methods of generating natural killer cells
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules

Also Published As

Publication number Publication date
KR101176146B1 (en) 2012-08-22
CA2476553A1 (en) 2003-08-21
AU2008249204A1 (en) 2008-12-18
IL207763A (en) 2014-07-31
WO2003068937A2 (en) 2003-08-21
KR20040094426A (en) 2004-11-09
AU2008249204B2 (en) 2011-03-10
EP1482787A4 (en) 2006-02-15
IL207763A0 (en) 2010-12-30
NZ534643A (en) 2010-06-25
EP1482787A2 (en) 2004-12-08
JP2010059193A (en) 2010-03-18
AU2003216286B2 (en) 2008-08-28
AU2003216286A1 (en) 2003-09-04
KR20110036114A (en) 2011-04-06
ZA200406356B (en) 2006-06-28
IL163439A (en) 2011-03-31
MXPA04007732A (en) 2004-10-15
JP2005517402A (en) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2003068937A3 (en) Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
Malgieri et al. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art
Shaw et al. Clinical applications of prenatal and postnatal therapy using stem cells retrieved from amniotic fluid
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
ATE365045T1 (en) PRODUCTION OF SOFT AND BONE TISSUE USING PRECURSOR CELLS FROM MUSCLE, AS WELL AS ASSOCIATED COMPOSITIONS AND FORMS OF TREATMENT
IL159637A (en) Composition for use in gene therapy comprising transduced cd34+ cells and their preparation
TW200740998A (en) Use of adipose tissue-derived stromal cells in spinal fusion
T Harris Umbilical cord tissue mesenchymal stem cells: characterization and clinical applications
WO2003066072A3 (en) Cell therapy using immunoregulatory t-cells
EP2336298A3 (en) Postpartum cells derived from placental tissue and methods of making and using the same
MXPA03006699A (en) Methods of inducing organ transplant tolerance and correcting hemoglobinopathies.
WO2007030811A3 (en) Tissue engineering methods and compositions
GB2441939A (en) Surgical membrane
AU2009240884A8 (en) Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
WO2005111204A3 (en) Porcine forssman synthetase cdna and polypeptide
EA200600076A1 (en) COMPOSITIONS AND METHODS OF INCREASING THE ACTIVITY OF TELOMERASE
WO2003025149A8 (en) Cell populations which co-express cd49c and cd90
WO2006078782A3 (en) Compositions containing agm cells and methods of use thereof
WO2001076615A3 (en) Cxcr4 agonist treatment of hematopoietic cells
DE69634982D1 (en) PROCESS FOR INCREASING HEMATOPOIETIC CELLS
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
WO2007139939A3 (en) Methods and compositions using immunomodulatory compounds in combination therapy
BR0312365A (en) Autologous human autologous progenitor mother cell culture medium, methods for the preparation thereof and a composition of human autologous progenitor mother cell and for obtaining autologous human progenitor muscle mother cells, use of an autologous human autologous progenitor culture medium human autologous progenitor mother cells, procedure for obtaining human autologous muscle progenitor mother cells and therapeutic procedure for autologous cell cardiomyoplasty, composition enriched with human autologous muscle progenitor mother cells and pharmaceutical composition
WO2005017160A3 (en) Mobilization of hematopoietic cells
WO2007044314A3 (en) Isolated embryonic-like stem cells derived from human umbilical cord blood

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007732

Country of ref document: MX

Ref document number: 163439

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004/06356

Country of ref document: ZA

Ref document number: 2003216286

Country of ref document: AU

Ref document number: 534643

Country of ref document: NZ

Ref document number: 2003568052

Country of ref document: JP

Ref document number: 200406356

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020047012604

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2476553

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003739817

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003739817

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 207763

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020117003297

Country of ref document: KR